The National Health Surveillance Agency (Anvisa) determined this Thursday (6) the prohibition of manufacturing, commercialization, and promotion of all batches of products from the brands Rare Cannabinoid, Canna River, and CBDFX, linked to the company CBD Brasil, for operating without authorization to import or sell in Brazil. 

According to Anvisa, the measure was taken based on Resolution-RE No. 4,409/2025, which prohibits the sale of products without prior registration or authorization. The agency emphasized that compliance with sanitary regulations is essential to ensure the safety and efficacy of cannabis-based products.

Company says it is acting “preventively” and defends compliance seal

In an official statement released this Friday (07), CBD Brasil, headquartered in Teresópolis/RJ, informed that it has preventively removed all pages and content related to cannabis-based products from its website, in compliance with Anvisa's decision. The company stated that it formally notified the agency and sent “technical evidence to GFIMP” (Management of Inspection and Monitoring of Products Subject to Health Surveillance).

“The measure reinforces our commitment to compliance, transparency, and responsible action. We understand that Anvisa's regulatory sweep is necessary and welcome, as it distinguishes serious, collaborative, and law-abiding companies from those without the same rigor,” the statement says.

CBD Brasil also highlighted that its portfolio includes other brands not affected by the measure, such as CBD KANU and cbdMD, and that it only maintains institutional and educational content online, without commercial offerings of the affected products.

In response to Portal Sechat, CEO Ricardo Guimarães stated that he sees Anvisa's action as part of a sector maturation process.

“Inspection is necessary and, for those who are compliant, it ends up being positive: at first, it hurts (adjustments, traffic drop), but it cleans the market, increases predictability, and strengthens serious brands, creating a more solid foundation for responsible prescription, investment, innovation, and regulatory compliance in Brazil,” he said.

According to Guimarães, the company has been in talks with sector leaders to strengthen transparency and governance practices.